Skip Navigation LinksHome > March 1, 2014 - Volume 65 - Issue 3 > Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1–Infe...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/01.qai.0000435600.65845.31
Basic and Translational Science

Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1–Infected Women in Uganda (HPTN 027): The First Pediatric HIV Vaccine Trial in Africa

Kaleebu, Pontiano MBChB, PhD*; Njai, Harr Freeya PhD*; Wang, Lei PhD; Jones, Norman BS; Ssewanyana, Isaac MSc§; Richardson, Paul MSc; Kintu, Kenneth MBChB; Emel, Lynda PhD; Musoke, Philippa MBChB¶,#; Fowler, Mary Glenn MD; Ou, San-San MS; Jackson, J. Brooks MD; Guay, Laura MD**; Andrew, Philip RN††; Baglyos, Lynn MS‡‡; Cao, Huyen MD; for the HPTN 027 protocol team

Collapse Box

Abstract

Objective: Maternal-to-child-transmission of HIV-1 infection remains a significant cause of HIV-1 infection despite successful prevention strategies. Testing protective HIV-1 vaccines remains a critical priority. The immunogenicity of ALVAC-HIV vCP1521 (ALVAC) in infants born to HIV-1–infected women in Uganda was evaluated in the first pediatric HIV-1 vaccine study in Africa.

Design: HIV Prevention Trials Network 027 was a randomized, double-blind, placebo-controlled phase I trial to evaluate the safety and immunogenicity of ALVAC in 60 infants born to HIV-1–infected mothers with CD4 counts of >500 cells per microliter, which were randomized to the ALVAC vaccine or placebo. ALVAC-HIV vCP1521 is an attenuated recombinant canarypox virus expressing HIV-1 clade E env, clade B gag, and protease gene products.

Methods: Infants were vaccinated at birth and 4, 8, and 12 weeks of age with ALVAC or placebo. Cellular and humoral immune responses were evaluated using interferon-γ enzyme-linked immunosorbent spot, carboxyfluorescein diacetate succinimidyl ester proliferation, intracellular cytokine staining, and binding and neutralizing antibody assays. Fisher exact test was used to compare positive responses between the study arms.

Results: Low levels of antigen-specific CD4 and CD8 T-cell responses (intracellular cytokine assay) were detected at 24 months (CD4—6/36 vaccine vs. 1/9 placebo; CD8—5/36 vaccine vs. 0/9 placebo) of age. There was a nonsignificant trend toward higher cellular immune response rates in vaccine recipients compared with placebo. There were minimal binding antibody responses and no neutralizing antibodies detected.

Conclusions: HIV-1–exposed infants are capable of generating low levels of cellular immune responses to ALVAC vaccine, similar to responses seen in adults.

© 2014 by Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.